title: [Evaluation of quality of life in arterial infusion chemotherapy of hepatocellular carcinoma].
abstract: We examined the quality of life in the arterial infusion chemotherapy of hepatocellular carcinoma patients using a questionnaire. The questionnaire used a category scale method of five grades. The questions about the quality of life covered ten areas for investigation (appetite, discomfort pain, nausea, daily activities, sleep, fatigue, time with family and friends, thinking about illness and confidence in the treatment). We added up scale points after one week and those after two weeks after the treatment. Patients after one-shot infusion showed aggravated scale points of anorexia and discomfort. Patients after transcatheter arterial embolization showed scale points of abdominal pain, general fatigue and discouragement about illness. Scale points in matters of thinking about illness and confidence in the treatment informed us about confidence in the course of treatment and comprehension of illness by cancer patients. How do we measure the quality of our care? This is difficult, but we thought the rate of being at home in survival might furnish us with much information in respect to the treatment and the quality of our care. In 36 patients with hepatocellular carcinoma treated with transcatheter arterial infusion and embolization, the arithmetic mean survival time after treatment was 412.1 days and time at home was 305.6 days. The rate of being at home doing survival time was 74.2% after the arterial infusion chemotherapy in 39 patients. The rate of being at home in 9 cases with one-shot infusion of Adriamycin was 43.5% (111 days); that in 9 cases with infusion of Mitomycin C microcapsules was 86.6% (716 days); that in 17 cases with transcatheter arterial embolization using spongel was 72.0% (234 days),; and that in 4 cases with infusion using implantable reservoir was 84.6% (220 days). In non-resected patients with chemotherapy, the rate of being at home was 20.3% for 61 cases of gastric cancer patients, 30.7% for 11 cases of colon cancer, 9.6% for 14 cases of gallbladder cancer and 39.8% for 112 cases of lung cancer. The arterial infusion and embolization of hepatocellular carcinoma has made it possible to lengthen the time that patients may stay home and thereby assure good quality of life.
authors.affiliation: Division of Internal Medicine, Niigata Cancer Center Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Niwa
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
authors.forename: K
authors.initials: K
authors.lastname: Ogoshi
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: A
authors.initials: A
authors.lastname: Nashimoto
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Akai
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000534:rehabilitation* / Q000628:therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D006499:Hepatic Artery; D006760:Hospitalization; D006801:Humans; D007260:Infusion Pumps; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000534:rehabilitation* / Q000628:therapy; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin